Hyundai BioLand Co Ltd
KOSDAQ:052260
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
TAL Education Group
NYSE:TAL
|
CN |
|
Inotiv Inc
NASDAQ:NOTV
|
US |
Hyundai BioLand Co Ltd
Accrued Liabilities
Hyundai BioLand Co Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hyundai BioLand Co Ltd
KOSDAQ:052260
|
Accrued Liabilities
₩3B
|
CAGR 3-Years
46%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
|
|
AmorePacific Corp
KRX:090430
|
Accrued Liabilities
₩121.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
2%
|
|
|
Amorepacific Group
KRX:002790
|
Accrued Liabilities
₩125.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
1%
|
|
|
Cosmax Inc
KRX:192820
|
Accrued Liabilities
₩31.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
23%
|
|
|
LG H&H Co Ltd
KRX:051900
|
Accrued Liabilities
₩304.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
Kolmar Korea Co Ltd
KRX:161890
|
Accrued Liabilities
₩135.2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
20%
|
CAGR 10-Years
41%
|
|
Hyundai BioLand Co Ltd
Glance View
HYUNDAI BIOLAND Co., Ltd. engages in the manufacture and sale of pharmaceutical and functional products. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2001-05-17. The firm operates its business through four segments. The Cosmetic Raw Material segment produces products such as portulaca extracts, ulmus extracts, crinum extracts, hyaluronic acids and arbutins. The Pharmaceutical Ingredient segment manufactures and sells products such as phellodendron extracts, ampelopsis extracts and gardenia extracts and others. The Ingredients for Health Functional Food segment produces and distributes red ginseng extract powders, seaweed powders, glucosamine powders, black garlic extract powders, dandelion extract powders, green tea extracts and others. The Medical Device segment involves in the provision of medical equipment such as tissue engineering products, comprised of biological wound dressings and collagen, as well as diagnostic kits, comprised of rapid kits, serological kits and mask packs.
See Also
What is Hyundai BioLand Co Ltd's Accrued Liabilities?
Accrued Liabilities
3B
KRW
Based on the financial report for Dec 31, 2025, Hyundai BioLand Co Ltd's Accrued Liabilities amounts to 3B KRW.
What is Hyundai BioLand Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
23%
Over the last year, the Accrued Liabilities growth was 168%. The average annual Accrued Liabilities growth rates for Hyundai BioLand Co Ltd have been 46% over the past three years , 15% over the past five years , and 23% over the past ten years .
